BMT Clinical Research Network Data Coordinating Center View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2001-2011

FUNDING AMOUNT

63255057 USD

ABSTRACT

DESCRIPTION (provided by applicant): Hematopoietic stem cell (HCT) transplantation offers curative therapy for a variety of malignant and nonmalignant disorders. It is limited by donor availability, transplant related toxicity, graft vs. host disease (GVHD), malignant relapse, infections, and for some patients, reduction in their post-transplant quality of life. Continuing progress from the previous funding period, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) proposes to develop and execute scientifically meritorious, prospective clinical trials addressing key issues in HCT. We will conduct multicenter Phase II and more importantly, prospective Phase III trials in six key areas including: alternative donors and graft sources;regimen related toxicity;GVHD;disease recurrence;infection and immune reconstitution;and late effects and quality of life. Due to the complexity of pediatric transplantation, especially in those with rare inherited disorders, which are complex and difficult to study, we will devote special attention and focused scientific expertise to using the coordinated strength of the Network to improve HCT outcomes for this unique population. The Network will also seek active collaboration with other scientific bodies including NCI- funded Cancer Cooperative Groups to improve the efficiency of clinical transplant studies for the large number of patients who could benefit from BMT and to maximize our successful completion of high quality and high priority clinical trials. This application proposes continued support of the BMT CTN by the Data and Coordinating Center (DCC) formed during the first funding cycle by a consortium of the Center for International Blood and Marrow Transplant Research, the National Marrow Donor Program and The EMMES Corporation. The DCC will continue comprehensive administrative, contracting, statistical and scientific activities to facilitate efficient use of Network resources and design and execution of high quality clinical trials. (End of abstract.) More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=7902190

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "63255057"
    }, 
    "description": "DESCRIPTION (provided by applicant): Hematopoietic stem cell (HCT) transplantation offers curative therapy for a variety of malignant and nonmalignant disorders. It is limited by donor availability, transplant related toxicity, graft vs. host disease (GVHD), malignant relapse, infections, and for some patients, reduction in their post-transplant quality of life. Continuing progress from the previous funding period, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) proposes to develop and execute scientifically meritorious, prospective clinical trials addressing key issues in HCT. We will conduct multicenter Phase II and more importantly, prospective Phase III trials in six key areas including: alternative donors and graft sources;regimen related toxicity;GVHD;disease recurrence;infection and immune reconstitution;and late effects and quality of life. Due to the complexity of pediatric transplantation, especially in those with rare inherited disorders, which are complex and difficult to study, we will devote special attention and focused scientific expertise to using the coordinated strength of the Network to improve HCT outcomes for this unique population. The Network will also seek active collaboration with other scientific bodies including NCI- funded Cancer Cooperative Groups to improve the efficiency of clinical transplant studies for the large number of patients who could benefit from BMT and to maximize our successful completion of high quality and high priority clinical trials. This application proposes continued support of the BMT CTN by the Data and Coordinating Center (DCC) formed during the first funding cycle by a consortium of the Center for International Blood and Marrow Transplant Research, the National Marrow Donor Program and The EMMES Corporation. The DCC will continue comprehensive administrative, contracting, statistical and scientific activities to facilitate efficient use of Network resources and design and execution of high quality clinical trials. (End of abstract.)", 
    "endDate": "2011-07-31T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.279885.9", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2691735", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2691735"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "U01HL069294"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "successful completion", 
      "clinical trials", 
      "previous funding period", 
      "recurrence;infection", 
      "immune reconstitution;and", 
      "curative therapy", 
      "DCC", 
      "clinical transplant studies", 
      "donor availability", 
      "prospective phase III trial", 
      "efficient use", 
      "National Marrow Donor Program", 
      "high quality", 
      "applicants", 
      "consortium", 
      "description", 
      "disorders", 
      "late effects", 
      "blood", 
      "alternative donors", 
      "prospective clinical trial", 
      "active collaboration", 
      "efficiency", 
      "key issues", 
      "malignant relapse", 
      "life", 
      "center", 
      "complexity", 
      "other scientific bodies", 
      "BMT CTN", 
      "pediatric transplantation", 
      "International Blood", 
      "quality", 
      "support", 
      "network", 
      "progress", 
      "EMMES Corporation", 
      "NCI-", 
      "coordinated strength", 
      "post-transplant quality", 
      "network resources", 
      "unique population", 
      "multicenter phase II", 
      "contracting", 
      "variety", 
      "transplant", 
      "scientific activity", 
      "execution", 
      "data", 
      "large number", 
      "nonmalignant disorders", 
      "transplantation", 
      "graft sources;regimen", 
      "special attention", 
      "hematopoietic stem cells", 
      "application", 
      "patients", 
      "BMT Clinical Research Network Data Coordinating Center", 
      "Marrow Transplant Clinical Trials Network", 
      "end", 
      "BMT", 
      "infection", 
      "toxicity", 
      "key areas", 
      "Coordinating Center", 
      "high priority", 
      "reduction", 
      "first funding cycle", 
      "Marrow Transplant Research", 
      "design", 
      "Cancer Cooperative Groups", 
      "graft vs. host disease", 
      "HCT outcomes", 
      "scientific expertise"
    ], 
    "name": "BMT Clinical Research Network Data Coordinating Center", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.30760.32", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.30760.32", 
          "name": "MEDICAL COLLEGE OF WISCONSIN", 
          "type": "Organization"
        }, 
        "familyName": "HOROWITZ", 
        "givenName": "MARY MARESCA", 
        "id": "sg:person.010360225632.91", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.010360225632.91", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2691735"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2021-01-20T02:58", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_20.xml.gz", 
    "startDate": "2001-09-30T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=7902190"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2691735'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2691735'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2691735'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2691735'


 

This table displays all metadata directly associated to this object as RDF triples.

118 TRIPLES      19 PREDICATES      95 URIs      87 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2691735 schema:about anzsrc-for:2211
2 schema:amount N1de50e031bfc4958955c990700fe57f9
3 schema:description DESCRIPTION (provided by applicant): Hematopoietic stem cell (HCT) transplantation offers curative therapy for a variety of malignant and nonmalignant disorders. It is limited by donor availability, transplant related toxicity, graft vs. host disease (GVHD), malignant relapse, infections, and for some patients, reduction in their post-transplant quality of life. Continuing progress from the previous funding period, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) proposes to develop and execute scientifically meritorious, prospective clinical trials addressing key issues in HCT. We will conduct multicenter Phase II and more importantly, prospective Phase III trials in six key areas including: alternative donors and graft sources;regimen related toxicity;GVHD;disease recurrence;infection and immune reconstitution;and late effects and quality of life. Due to the complexity of pediatric transplantation, especially in those with rare inherited disorders, which are complex and difficult to study, we will devote special attention and focused scientific expertise to using the coordinated strength of the Network to improve HCT outcomes for this unique population. The Network will also seek active collaboration with other scientific bodies including NCI- funded Cancer Cooperative Groups to improve the efficiency of clinical transplant studies for the large number of patients who could benefit from BMT and to maximize our successful completion of high quality and high priority clinical trials. This application proposes continued support of the BMT CTN by the Data and Coordinating Center (DCC) formed during the first funding cycle by a consortium of the Center for International Blood and Marrow Transplant Research, the National Marrow Donor Program and The EMMES Corporation. The DCC will continue comprehensive administrative, contracting, statistical and scientific activities to facilitate efficient use of Network resources and design and execution of high quality clinical trials. (End of abstract.)
4 schema:endDate 2011-07-31T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.279885.9
6 schema:identifier N6689d3b99ab44a9ab05e3f9fa79bf7ce
7 N668a96c5cd8246f98fae179035dcf4c6
8 schema:inLanguage en
9 schema:keywords BMT
10 BMT CTN
11 BMT Clinical Research Network Data Coordinating Center
12 Cancer Cooperative Groups
13 Coordinating Center
14 DCC
15 EMMES Corporation
16 HCT outcomes
17 International Blood
18 Marrow Transplant Clinical Trials Network
19 Marrow Transplant Research
20 NCI-
21 National Marrow Donor Program
22 active collaboration
23 alternative donors
24 applicants
25 application
26 blood
27 center
28 clinical transplant studies
29 clinical trials
30 complexity
31 consortium
32 contracting
33 coordinated strength
34 curative therapy
35 data
36 description
37 design
38 disorders
39 donor availability
40 efficiency
41 efficient use
42 end
43 execution
44 first funding cycle
45 graft sources;regimen
46 graft vs. host disease
47 hematopoietic stem cells
48 high priority
49 high quality
50 immune reconstitution;and
51 infection
52 key areas
53 key issues
54 large number
55 late effects
56 life
57 malignant relapse
58 multicenter phase II
59 network
60 network resources
61 nonmalignant disorders
62 other scientific bodies
63 patients
64 pediatric transplantation
65 post-transplant quality
66 previous funding period
67 progress
68 prospective clinical trial
69 prospective phase III trial
70 quality
71 recurrence;infection
72 reduction
73 scientific activity
74 scientific expertise
75 special attention
76 successful completion
77 support
78 toxicity
79 transplant
80 transplantation
81 unique population
82 variety
83 schema:name BMT Clinical Research Network Data Coordinating Center
84 schema:recipient Nff1f80032d97402e8348998596bceb0c
85 sg:person.010360225632.91
86 https://www.grid.ac/institutes/grid.30760.32
87 schema:sameAs https://app.dimensions.ai/details/grant/grant.2691735
88 schema:sdDatePublished 2021-01-20T02:58
89 schema:sdLicense https://scigraph.springernature.com/explorer/license/
90 schema:sdPublisher N2be886c1a4a843d6af2d20e68e23e0d2
91 schema:startDate 2001-09-30T00:00:00Z
92 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=7902190
93 sgo:license sg:explorer/license/
94 sgo:sdDataset grants
95 rdf:type schema:MonetaryGrant
96 N1de50e031bfc4958955c990700fe57f9 schema:currency USD
97 schema:value 63255057
98 rdf:type schema:MonetaryAmount
99 N2be886c1a4a843d6af2d20e68e23e0d2 schema:name Springer Nature - SN SciGraph project
100 rdf:type schema:Organization
101 N6689d3b99ab44a9ab05e3f9fa79bf7ce schema:name nih_id
102 schema:value U01HL069294
103 rdf:type schema:PropertyValue
104 N668a96c5cd8246f98fae179035dcf4c6 schema:name dimensions_id
105 schema:value 2691735
106 rdf:type schema:PropertyValue
107 Nff1f80032d97402e8348998596bceb0c schema:member sg:person.010360225632.91
108 schema:roleName PI
109 rdf:type schema:Role
110 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
111 rdf:type schema:DefinedTerm
112 sg:person.010360225632.91 schema:affiliation https://www.grid.ac/institutes/grid.30760.32
113 schema:familyName HOROWITZ
114 schema:givenName MARY MARESCA
115 rdf:type schema:Person
116 https://www.grid.ac/institutes/grid.279885.9 schema:Organization
117 https://www.grid.ac/institutes/grid.30760.32 schema:name MEDICAL COLLEGE OF WISCONSIN
118 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...